缩写名/全名 |
ENDOCR-RELAT CANCER
ENDOCRINE-RELATED CANCER |
||||||||||||||||||||||||||||
ISSN号 | 1351-0088 | ||||||||||||||||||||||||||||
研究方向 | 医学-内分泌学与代谢 | ||||||||||||||||||||||||||||
影响因子 | 2015:4.472, 2016:5.267, 2017:5.331, 2018:4.774, 2019:4.8, | ||||||||||||||||||||||||||||
出版国家 | ENGLAND | ||||||||||||||||||||||||||||
出版周期 | Quarterly | ||||||||||||||||||||||||||||
年文章数 | 112 | ||||||||||||||||||||||||||||
出版年份 | 1994 | ||||||||||||||||||||||||||||
是否OA | No | ||||||||||||||||||||||||||||
审稿周期(仅供参考) | 较慢,6-12周 |
||||||||||||||||||||||||||||
录用比例 | 一般 | ||||||||||||||||||||||||||||
投稿链接 | http://www.endocrinology-journals.org/site/misc/submit-online.xhtml | ||||||||||||||||||||||||||||
投稿官网 | http://erc.endocrinology-journals.org/ | ||||||||||||||||||||||||||||
h-index | 119 | ||||||||||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1351-0088%5BISSN%5D | ||||||||||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Non-secreting pituitary tumours characterised by enhanced expression of YAP/TAZ. Author: Xekouki P1,2, Lodge EJ1,3, Matschke J4, Santambrogio A1,5, Apps JR6,7, Sharif A8, Jacques TS6,7, Aylwin S2, Prevot V8, Li R9, Flitsch J10, Bornstein SR3,5, Theodoropoulou M11, Andoniadou CL1,5. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):215-225. doi: 10.1530/ERC-18-0330. PubMed DOI |
2. | Antitumor effects of anlotinib in thyroid cancer. Author: Ruan X1, Shi X2, Dong Q2, Yu Y1, Hou X1, Song X2, Wei X3, Chen L2, Gao M1. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):153-164. doi: 10.1530/ERC-17-0558. PubMed DOI |
3. | KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer. Author: Luo XH1, Liu JZ1, Wang B1, Men QL1, Ju YQ1, Yin FY1, Zheng C1, Li W2. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):181-195. doi: 10.1530/ERC-18-0383. PubMed DOI |
4. | Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. Author: Guan W1, Hu J1,2,3, Yang L4, Tan P4, Tang Z4, West BL5, Bollag G5, Xu H1, Wu L3,6,7,8,9. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):131-140. doi: 10.1530/ERC-18-0284. PubMed DOI |
5. | ATM deficiency promotes progression of CRPC by enhancing Warburg effect. Author: Xu L1,2, Ma E3, Zeng T2,4, Zhao R5, Tao Y2, Chen X2, Groth J2, Liang C1, Hu H2,6, Huang J2,6,7. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):59-71. doi: 10.1530/ERC-18-0196. PubMed DOI |
6. | KAT5 promotes invasion and metastasis through C-MYC stabilization in ATC. Author: Wei X1, Cai S2,3, Boohaker RJ2, Fried J2, Li Y4, Hu L5, Pan Y5, Cheng R5, Zhang S1, Tian Y3, Gao M5, Xu B2,6. Journal: Endocr Relat Cancer. 2019 Jan 1;26(1):141-151. doi: 10.1530/ERC-18-0193. PubMed DOI |
7. | SOX30 is a prognostic biomarker and chemotherapeutic indicator for advanced-stage ovarian cancer. Author: Han F1, Liu WB2, Li JJ3, Zhang MQ4, Yang JT5, Zhang X6, Hao XL7, Yin L8, Mao CY9, Jiang X10, Cao J11, Liu JY12. Journal: Endocr Relat Cancer. 2019 Jan 1. pii: ERC-18-0529.R1. doi: 10.1530/ERC-18-0529. [Epub ahead of print] PubMed DOI |
8. | Roles of the HOXA10 gene during castrate-resistant prostate cancer progression. Author: Long Z1,2, Li Y2, Gan Y2,3, Zhao D4,5,6, Wang G4,5,6, Xie N2, Lovnicki JM2, Fazli L2, Cao Q7, Chen K4,5,6, Dong X2. Journal: Endocr Relat Cancer. 2019 Mar 1;26(3):279-292. doi: 10.1530/ERC-18-0465. PubMed DOI |
9. | Targeting autophagy in thyroid cancers. Author: Wei WJ1, Hardin H2, Luo QY3. Journal: Endocr Relat Cancer. 2019 Jan 1. pii: ERC-18-0502.R1. doi: 10.1530/ERC-18-0502. [Epub ahead of print] PubMed DOI |
10. | Exosomes increased angiogenesis in papillary thyroid cancer microenvironment. Author: Wu F1, Li F2, Lin X3, Xu F4, Cui R5, Zhong J6, Zhu T7, Shan SK8, Liao XB9, Yuan L10, Mo Z11. Journal: Endocr Relat Cancer. 2019 Mar 1. pii: ERC-19-0008.R1. doi: 10.1530/ERC-19-0008. [Epub ahead of print] PubMed DOI |
|
|